Showing results (231-240 of 276) with videos related to
Sort By:
Pageof 28
Cancer Discovery|May 16, 2012
Prevention of persistent human papillomavirus infection by an HPV16/18 vaccine: a community-based randomized clinical trial in Guanacaste, Costa RicaRolando Herrero, Sholom Wacholder, Ana C Rodríguez, et al.Journal of the National Cancer Institute|September 13, 2011
Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccineAimée R Kreimer, Ana Cecilia Rodriguez, Allan Hildesheim, et al.Journal of Virology|March 29, 2013
Phylogenetic considerations in designing a broadly protective multimeric L2 vaccineSubhashini Jagu, Kihyuck Kwak, John T Schiller, et al.Proceedings of the National Academy of Sciences of the United States of America|September 18, 2016
Leveraging premalignant biology for immune-based cancer preventionAvrum Spira, Mary L Disis, John T Schiller, et al.European Urology Open Science|June 22, 2026
Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder CancerJennifer Linehan, Piyush K Agarwal, Xianne Penny, et al.The Journal of Infectious Diseases|October 23, 1997
Seroreactivity to human papillomavirus type 16 virus-like particles is lower in high-risk men than in high-risk womenE I Svare, S K Kjaer, B Nonnenmacher, et al.Journal of the National Cancer Institute. Monographs|November 12, 2024
HPV16/18 antibodies 16-years after single dose of bivalent HPV vaccination: Costa Rica HPV vaccine trialCarolina Porras, Byron Romero, Troy Kemp, et al.Journal of the National Cancer Institute|October 16, 2015
Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV InfectionDaniel C Beachler, Aimée R Kreimer, Mark Schiffman, et al.Journal of the National Cancer Institute|May 7, 1997
Immunoglobulin G responses against human papillomavirus type 16 virus-like particles in a prospective nonintervention cohort study of women with cervical intraepithelial neoplasiaT D de Gruijl, H J Bontkes, J M Walboomers, et al.Journal of the National Cancer Institute|April 11, 2023
Estimating human papillomavirus vaccine efficacy from a single-arm trial: proof-of-principle in the Costa Rica Vaccine TrialBrian Befano, Nicole G Campos, Didem Egemen, et al.Pageof 28